New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene…

The new drug application (NDA) for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that habor an NTRK gene fusion has been completed.

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply